– More than $2.6 billion in cash, cash equivalents, investments and profit-share payments to be received from GSK expected to fund the company’s ongoing operations and liabilities for up to five years –
Read more at globenewswire.comVir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
